Revenue
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Decoy Therapeutics Inc. (DCOY)
Price$2.79Cached quote
Net income
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2014
2015
2016
2017
2018
2019
2020
2021
2022
2024
2025
Total cash / debt
CashTotal debt
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $1.8M | $5.2M | $3.5M | $2.0M | $1.3M | $1.0M | $0 | $0 |
| Gross profit | — | — | — | — | — | — | — | $1.5M | $767,969 | $347,916 | $0 | $0 |
| Gross margin | — | — | — | — | — | — | — | 77.93% | 60.26% | 34.42% | — | — |
| Research & development | $8.5M | $0 | $7.2M | $15.8M | $8.5M | $6.9M | $4.0M | $1.3M | $17.0M | $20.4M | $12.7M | $4.0M |
| Operating expenses | $12.6M | $5.7M | $12.9M | $31.8M | $14.7M | $13.0M | $11.7M | $3.6M | $36.0M | $40.9M | $29.2M | $8.0M |
| Operating income | −$12.6M | −$5.7M | −$12.9M | −$31.8M | −$12.8M | −$7.8M | −$8.3M | −$1.7M | −$34.7M | −$39.9M | −$29.2M | −$8.0M |
| Operating margin | — | — | — | — | −696.27% | −148.78% | −238.53% | −86.33% | −2,724.65% | −3,946.54% | — | — |
| EBITDA | −$12.6M | −$5.7M | −$12.9M | −$31.8M | −$12.8M | −$7.8M | −$8.1M | −$1.7M | −$34.4M | −$39.6M | −$29.2M | −$8.0M |
| EBITDA margin | — | — | — | — | −695.23% | −148.44% | −234.85% | −85.46% | −2,699.18% | −3,919.11% | — | — |
| Net income | −$12.5M | −$5.6M | −$12.5M | −$31.6M | −$12.8M | −$7.4M | −$6.9M | −$1.7M | −$34.4M | −$39.5M | −$29.1M | −$8.0M |
| Net profit margin | — | — | — | — | −693.84% | −140.49% | −200.18% | −85.56% | −2,701.74% | −3,907.65% | — | — |
| Basic EPSper basic share | -$129.10 | -$69.54 | -$460.87 | -$1,784.71 | -$925.94 | -$1,499.25 | -$6,356.82 | -$3,478.26 | -$5,967.02 | -$7,286.36 | -$6,236.88 | -$13,703.15 |
| Diluted EPSper diluted share | -$129.10 | -$69.54 | -$460.87 | -$1,784.71 | -$925.94 | -$1,499.25 | -$6,356.82 | -$3,478.26 | -$5,967.02 | -$7,286.36 | -$6,236.88 | -$13,703.15 |
Owners
Reported shareholders
≈3.79%of listed shares
Rosenblum Mark J20.18K shares · Nov 20, 2025
View holders
| Holder | % owned |
|---|---|
Rosenblum Mark J | ≈3.79%20.18K shares |
PIERCE FREDERICK II | ≈3.13%16.67K shares |
HANISH ARNOLD C | ≈0.94%5K shares |
VANGUARD CAPITAL MANAGEMENT LLC | 0.76%4.03K shares |
Tower Research Capital LLC (TRC) | 0.05%256 shares |
UBS Group AG | <0.01%25 shares |
Caitong International Asset Management Co., Ltd | <0.01%2 shares |
Percentages use 531.97K shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 4 ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Dec 30, 2025Form 4 | HANISH ARNOLD CDirector | SellCommon Stock | 12 | $0.64 | $7.68 | 0 |
| Dec 30, 2025Form 4 | HANISH ARNOLD CDirector | SellCommon Stock · indirect | 15 | $0.64 | $9.60 | 5.0K |
| Nov 20, 2025Form 4 | HANISH ARNOLD CDirector | BuyCommon Stock · indirect | 5.0K | $0.75 | $3.8K | 5.0K |
| Nov 20, 2025Form 4 | Rosenblum Mark JExec VP Finance, CFO | BuyCommon Stock | 20.0K | $0.80 | $16.0K | 20.2K |